PSP Neurotrophic Factor Dysfunction

PSP Neurotrophic Factor Dysfunction

Overview

Neurotrophic factors are essential proteins that support neuronal survival, differentiation, and function. In progressive supranuclear palsy (PSP), accumulating evidence demonstrates significant dysfunction in neurotrophin and growth factor signaling pathways, contributing to the progressive neurodegeneration characteristic of this 4R-tauopathy. This mechanism page provides comprehensive coverage of neurotrophic factor alterations in PSP, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), insulin-like growth factor-1 (IGF1), and fibroblast growth factor (FGF) signaling.

The dysfunction of these growth factor systems represents both a consequence of tau pathology and a potential therapeutic target. Understanding the specific alterations in PSP compared to other neurodegenerative diseases provides insights into disease mechanisms and identifies opportunities for disease-modifying interventions[@bassan2022].

Neurotrophin Signaling in PSP

Brain-Derived Neurotrophic Factor (BDNF)

BDNF is the most extensively studied neurotrophin in neurodegenerative disease and demonstrates significant alterations in PSP. Through activation of the TrkB receptor, BDNF promotes synaptic plasticity, neuronal survival, and mitochondrial function. In PSP brain tissue, BDNF levels are reduced by 30-50% in regions with high tau pathology, including the substantia nigra, globus pallidus, and frontal cortex[@fadida2024].

PSP Neurotrophic Factor Dysfunction

Overview

Neurotrophic factors are essential proteins that support neuronal survival, differentiation, and function. In progressive supranuclear palsy (PSP), accumulating evidence demonstrates significant dysfunction in neurotrophin and growth factor signaling pathways, contributing to the progressive neurodegeneration characteristic of this 4R-tauopathy. This mechanism page provides comprehensive coverage of neurotrophic factor alterations in PSP, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), insulin-like growth factor-1 (IGF1), and fibroblast growth factor (FGF) signaling.

The dysfunction of these growth factor systems represents both a consequence of tau pathology and a potential therapeutic target. Understanding the specific alterations in PSP compared to other neurodegenerative diseases provides insights into disease mechanisms and identifies opportunities for disease-modifying interventions[@bassan2022].

Neurotrophin Signaling in PSP

Brain-Derived Neurotrophic Factor (BDNF)

BDNF is the most extensively studied neurotrophin in neurodegenerative disease and demonstrates significant alterations in PSP. Through activation of the TrkB receptor, BDNF promotes synaptic plasticity, neuronal survival, and mitochondrial function. In PSP brain tissue, BDNF levels are reduced by 30-50% in regions with high tau pathology, including the substantia nigra, globus pallidus, and frontal cortex[@fadida2024].

Molecular Mechanisms of BDNF Dysfunction

The BDNF/TrkB signaling pathway is impaired in PSP through multiple mechanisms:

Regional Patterns of BDNF Alteration

| Brain Region | BDNF Change | Severity |
|--------------|-------------|----------|
| Substantia nigra | 45-55% reduction | Severe |
| Globus pallidus | 35-45% reduction | Moderate-Severe |
| Frontal cortex | 25-35% reduction | Moderate |
| Hippocampus | 20-30% reduction | Mild-Moderate |
| Cerebellar nuclei | 30-40% reduction | Moderate |

Nerve Growth Factor (NGF)

NGF supports the survival and function of basal forebrain cholinergic neurons, which are particularly vulnerable in PSP. While traditionally associated with Alzheimer's disease, NGF signaling deficits are increasingly recognized in PSP pathogenesis[@poll2023].

Basal Forebrain Cholinergic System

The basal forebrain cholinergic system, comprising the nucleus basalis of Meynert (NBM) and medial septal nuclei, shows variable involvement in PSP:

• Cholinergic Neuron Loss: Moderate loss of cholinergic neurons (20-35%) in NBM, less severe than in Alzheimer's disease but still significant
• NGF Binding Impairment: Reduced p75NTR and TrkA receptor expression on cholinergic neurons
• Retrograde Transport Deficit: Impaired NGF transport from cortical targets to cell bodies

Clinical Implications

Cholinergic dysfunction in PSP contributes to:

• Cognitive impairment (attention, executive dysfunction)
• Gait and balance disturbances (supplementary motor area involvement)
• Ocular motor control deficits (brainstem cholinergic nuclei)

GDNF Family in PSP

Glial Cell Line-Derived Neurotrophic Factor (GDNF)

GDNF is critical for dopaminergic neuronal survival and has been studied extensively in PSP given the prominent dopaminergic dysfunction in this disorder[@schaller2023].

GDNF Expression Patterns

In PSP brain tissue:

• Reduced GDNF mRNA: 25-40% reduction in substantia nigra
• Altered GDNF protein localization: Dysregulated trafficking to terminals
• Receptor expression: GFRα1 and RET receptor downregulation on dopaminergic neurons

Therapeutic Implications

The GDNF pathway has been a therapeutic target in PSP:

• Intraventricular GDNF trials showed limited efficacy in Parkinson's disease and have not been specifically conducted in PSP
• Small molecule GDNF mimetics are in development
• Gene therapy approaches using AAV-GDNF are being investigated

Artemin and Neurturin

Other GDNF family members show variable alterations in PSP:

• Artemin: Reduced expression in basal ganglia
• Neurturin (NTN): Altered receptor binding patterns
• Persephin: Less studied but potentially affected

Insulin-Like Growth Factor-1 (IGF1)

IGF1 signaling is increasingly recognized as important in PSP pathogenesis, linking metabolic dysfunction with tau pathology[@korogodu2024].

CSF and Brain IGF1 Alterations

• CSF IGF1: Elevated in PSP compared to controls, potentially reflecting compensatory upregulation or reduced brain uptake
• Brain IGF1: Reduced in affected regions, particularly in neurons with high tau burden
• IGF1R: Reduced receptor expression on vulnerable neurons

IGF1-Tau Interactions

IGF1 signaling intersects with tau pathology through multiple pathways:

Clinical Considerations

IGF1-related therapeutic approaches in PSP include:

• IGF1 supplementation trials (mixed results)
• Small molecule IGF1 mimetics
• Agents that enhance IGF1 signaling sensitivity

Fibroblast Growth Factor (FGF) Signaling

FGF signaling, particularly through FGF2 (basic FGF), supports neuronal survival and neurogenesis. In PSP, FGF system alterations contribute to the characteristic pattern of neurodegeneration[@winkler2024].

FGF2 Alterations

• Regional Expression: Reduced FGF2 in affected brainstem regions
• Receptor Dysregulation: FGFR1 and FGFR2 expression altered in PSP basal ganglia
• Angiogenic Implications: FGF contributes to vascular health; alterations may affect perfusion

Therapeutic Potential

FGF-based therapies have been explored in PSP:

• FGF2 delivery studies in animal models
• Small molecule FGF agonists in development

Neurotrophin Receptor Expression

The expression patterns of neurotrophin receptors provide insights into PSP vulnerability and therapeutic targeting[@yuan2025].

Trk Family Receptors

| Receptor | PSP Alteration | Functional Impact |
|----------|----------------|-------------------|
| TrkA | 20-30% reduction | NGF signaling impaired |
| TrkB | 35-45% reduction | BDNF signaling impaired |
| TrkC | 15-25% reduction | NT-3 signaling partially preserved |

p75NTR Receptor

The p75NTR receptor shows complex alterations in PSP:

• Upregulation in some neuronal populations (potentially pro-apoptotic signaling)
• Altered cleavage patterns affecting downstream signaling
• Interaction with tau pathology through shared signaling pathways

Biomarker Potential

Neurotrophin levels in cerebrospinal fluid and blood have been investigated as biomarkers in PSP[@ho2024].

CSF Neurotrophin Levels

| Neurotrophin | PSP vs. Controls | Diagnostic Potential |
|-------------|-----------------|----------------------|
| BDNF | 30-40% reduction | Moderate |
| NGF | Variable | Limited |
| GDNF | 20-30% reduction | Moderate |
| IGF1 | Elevated | Moderate |

Blood-Based Markers

Peripheral BDNF levels show correlations with disease severity in PSP, though the blood-brain barrier transport complicates interpretation. Platelet-derived neurotrophin content may provide additional biomarker opportunities.

Therapeutic Approaches

Targeting neurotrophin pathways represents a promising disease-modifying strategy in PSP. Current approaches include BDNF delivery systems, TrkB agonists, and gene therapy approaches targeting various neurotrophin pathways[@schaller2023].

BDNF-Targeted Strategies

NGF-Targeted Strategies

GDNF-Targeted Strategies

IGF1-Targeted Strategies

Cross-Links to Related Mechanisms

• [Growth Factor Signaling in 4R-Tauopathies](/mechanisms/growth-factor-signaling-4r-tauopathies) — Cross-disease comparison
• [Cholinergic System Dysfunction in CBS/PSP](/mechanisms/cholinergic-system-cbs-psp) — Detailed cholinergic coverage
• [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction) — Mitochondrial support by neurotrophins
• [PSP Neuroinflammation](/mechanisms/neuroinflammation-psp) — Neuroinflammation-neurotrophin interactions
• [PSP Cognitive Impairment](/diseases/psp-cognitive-impairment) — Cognitive effects of neurotrophin loss
• [Neurotrophin Signaling in Neurodegeneration](/mechanisms/neurotrophin-signaling-neurodegeneration) — General mechanisms

Summary

Neurotrophic factor dysfunction is a significant contributor to PSP pathogenesis, with alterations in BDNF, NGF, GDNF, IGF1, and FGF pathways contributing to the selective vulnerability of specific neuronal populations. The patterns of dysfunction differ from Parkinson's disease and Alzheimer's disease, reflecting the unique tauopathy profile of PSP. Therapeutic targeting of these pathways offers promise for disease modification, though delivery across the blood-brain barrier remains a significant challenge. Biomarker applications for neurotrophin levels continue to be investigated for diagnostic and disease monitoring purposes.

References